As Pfizer’s Legal Director overseeing Greece, Cyprus, Malta, and Israel, Stathis Mihos explores EU health policy advancements and the complexities arising from the pandemic and examines how artificial intelligence is dynamically influencing lawyers’ work.

Greece’s vibrant life sciences sector is supported by a robust regulatory framework and expanding investment opportunities. In the following paragraphs, we will examine key aspects of product liability, intellectual property (IP), artificial intelligence (AI), and investment potential within the Greek life sciences landscape, highlighting the laws and regulations that shape the industry.

Following extensive discussions between industry stakeholders and state institutions, several crucial solutions have been identified to address the problems of drug availability and monitoring control. The primary aim is to ensure wider and faster access to medicinal products for patients in Latvia.

Digitization is affecting many sectors and healthcare is no exception. It is a key tool for speeding up and streamlining processes that can significantly improve the quality and availability of medical care. In the Czech Republic, the overall level of digitization in healthcare is still low.

It is not new that originator pharmaceutical companies try to block generic competitors from entering the market. Considering the recent developments in the Court of Justice of the European Union (CJEU), originators should tread carefully when defending their patents. Having a strong patent is crucial, and the consequences of failing to vet the strength of a patent could end up costly.

Healthcare is a fundamental component of any society, reflecting its core values and priorities. In Lithuania, the healthcare system is marked by a pronounced division between private and public hospitals. Lithuania’s healthcare services are divided into outpatient (ambulatory) and inpatient (stationary) services.